Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$1.09B in Q4 2024 → $177M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| PM Parabilis Medicines, Inc. | 64.4% | New | 4,166,666 | $114M |
| Intellia Therapeutics, Inc. | 35.4% | Unchanged | 3,702,995 | $62.7M |
| Adicet Bio, Inc. | 0.3% | New | 60,511 | $523K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed August 07, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| PM Parabilis Medicines, Inc. | New | +4,166,666 | +$114M | 64.4% |
| Adicet Bio, Inc. | New | +60,511 | +$523K | 0.3% |
| Adicet Bio, Inc. | Exited | −60,511 | −$412K | — |
quarter ended March 31, 2026 · filed May 08, 2026
No position changes this quarter.
quarter ended December 31, 2025 · filed February 06, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. | Exited | −1,392,303 | −$635M | — |
| Adicet Bio, Inc. | Trimmed | −907,672 | −$7.64M | 1.5% |
| Adverum Biotechnologies, Inc. | Exited | −180,909 | −$820K | — |
quarter ended September 30, 2025 · filed November 07, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. | Trimmed | −3,052,142 | −$1.39B | 90.6% |
quarter ended June 30, 2025 · filed August 01, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| 2seventy Bio, Inc. | Exited | −1,254,827 | −$6.2M | — |
| Bluebird Bio, Inc. | Exited | −21,000 | −$102K | — |
quarter ended March 31, 2025 · filed May 02, 2025
No position changes this quarter.
Loading...
